Sorafenib
Overview
Sorafenib is a multi-kinase inhibitor used in the treatment of liver, kidney, and thyroid cancers. It works by inhibiting tumor cell proliferation and angiogenesis.
API suppliers (7)
Suppliers of Sorafenib evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
6 of 7 hold a GMP certificate on record in the EU or UK registers
- MSN Laboratories Private LimitedIndia3 active DMF GMP on record
- Cipla USA, Inc.USA2 active DMF
- Hetero Labs LimitedIndia1 active DMF GMP on record
- Alembic Pharmaceuticals LimitedIndia1 active DMF GMP on record
- APITORIA PHARMA PRIVATE LTDIndia1 active DMF GMP on record
- Granules India LimitedIndia1 active DMF GMP on record
- Zhejiang Jiuzhou Pharmaceutical Co., Ltd.China GMP on record
Patent & exclusivity (US)
Per the FDA Orange Book (6 approved US products), the latest listed US patent on Sorafenib expires 10 Sept 2028. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Sorafenib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.